Benitec Biopharma Ltd ADR (BNTC) - Total Liabilities
Based on the latest financial reports, Benitec Biopharma Ltd ADR (BNTC) has total liabilities worth $3.32 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore BNTC net asset momentum to track the company's year-over-year net asset growth rate.
Benitec Biopharma Ltd ADR - Total Liabilities Trend (2013–2025)
This chart illustrates how Benitec Biopharma Ltd ADR's total liabilities have evolved over time, based on quarterly financial data. See Benitec Biopharma Ltd ADR free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Benitec Biopharma Ltd ADR Competitors by Total Liabilities
The table below lists competitors of Benitec Biopharma Ltd ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wuhan Ligong Guangke Co Ltd
SHE:300557
|
China | CN¥754.18 Million |
|
Power Wind Health Industry Incorporated
TW:8462
|
Taiwan | NT$9.35 Billion |
|
Qurient Co. Ltd
KQ:115180
|
Korea | ₩21.88 Billion |
|
Attica Holdings S.A.
AT:ATTICA
|
Greece | €855.40 Million |
|
CN EVERBRIGHT WATER HD 1
F:BIU2
|
Germany | €23.18 Billion |
|
Yingde Greatchem Chemicals Co. Ltd. A
SHE:300804
|
China | CN¥783.77 Million |
|
Dalian Thermal Power Co Ltd
SHG:600719
|
China | CN¥1.85 Billion |
|
GMM Pfaudler Limited
NSE:GMMPFAUDLR
|
India | Rs27.91 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Benitec Biopharma Ltd ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BNTC stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 67.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Benitec Biopharma Ltd ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Benitec Biopharma Ltd ADR (2013–2025)
The table below shows the annual total liabilities of Benitec Biopharma Ltd ADR from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $2.30 Million | -53.71% |
| 2024-06-30 | $4.96 Million | +16.42% |
| 2023-06-30 | $4.26 Million | +37.88% |
| 2022-06-30 | $3.09 Million | +125.79% |
| 2021-06-30 | $1.37 Million | -9.10% |
| 2020-06-30 | $1.51 Million | -42.90% |
| 2019-06-30 | $2.64 Million | +38.36% |
| 2018-06-30 | $1.91 Million | +113.85% |
| 2017-06-30 | $891.40K | +13.36% |
| 2016-06-30 | $786.36K | -37.56% |
| 2015-06-30 | $1.26 Million | -18.53% |
| 2014-06-30 | $1.55 Million | +77.38% |
| 2013-06-30 | $871.53K | -- |
About Benitec Biopharma Ltd ADR
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single a… Read more